1. Hungary Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Gedeon Richter PLC

Gedeon Richter PLC

RGEDF
Gedeon Richter PLCUS flagOther OTC
42.03
USD
+0.53
- -
7.69BMarket Cap
Gedeon Richter PLC
RGEDF
(Other OTC)

Recent

price

42.03

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
1,478.9
1,655.12
1,763.89
1,891.95
1,911.85
1,971.11
2,096.82
2,386.18
2,391.04
2,729.91
3,047.66
3,390.15
4,308.17
4,357.65
4,685.63
5,080.24
4,404.54
Revenue per Share
347.23
264.94
265.85
229.94
134.86
290.7
356.21
47.71
189.72
253.4
562.9
750.65
907.39
859.72
1,307.23
1,270.58
1,243.76
Basic EPS, GAAP
-75.37
272.5
173.62
216.87
102.52
333.24
220.43
235.3
226.97
215.73
359.64
-18.24
614.05
157.12
1,178.32
1,148.43
674.05
Free Cash Flow per Basic Share
76.86
85.98
65.9
65.93
57.31
33.7
72.98
106.09
68.02
101.34
72.59
226.55
226.19
394.35
432.09
509
428.46
Dividend per Share
2,358.16
2,626.63
2,781.04
2,944.85
3,012.17
3,315.59
3,642.56
3,538.9
3,657.19
3,866.34
4,344.46
4,922.99
5,718.86
6,186.99
7,130.46
7,667.14
6,408.79
Book Value per Share
1,393.43
1,586.28
1,807.44
1,889.04
1,857.28
2,153.1
2,238.68
2,468.98
2,651.55
3,020.15
3,414.68
3,545.89
4,472.19
4,751.95
5,208.79
5,827.2
4,570.62
Tangible Book Value per Share
186
186
185
186
185
185
186
186
186
186
186
186
186
185
183
183
184
Basic Weighted Avg Shares
275,312
307,868
326,702
351,886
353,709
365,220
389,690
444,356
445,484
507,794
566,776
630,595
802,755
805,158
857,545
928,962
811,415
Sales/Revenue/Turnover
22.76
19.79
14.91
13.2
10.67
18.26
16.07
16.86
16.53
16.47
23.12
23
25.29
30.6
31.54
35.19
33.18
Operating Margin (%)
21,135
24,459
26,883
28,301
29,363
31,248
32,895
34,747
34,907
39,320
39,846
44,922
48,569
50,808
52,760
60,463
49,650
Depreciation Expense
64,640
49,281
49,240
42,766
24,950
53,863
66,200
8,885
35,348
47,135
104,683
139,626
169,076
158,850
239,244
232,335
229,129
Net Income, GAAP
4.63
0.44
1.69
2.76
2.95
10.04
1.76
27.56
17.66
4.76
7.91
3.68
- -
6.35
14.78
18.44
9.75
Effective Tax Rate (%)
23.48
16.01
15.07
12.15
7.05
14.75
16.99
2
7.93
9.28
18.47
22.14
21.06
19.73
27.9
25.01
28.24
Profit Margin (%)
181,735
202,675
240,422
226,906
197,702
236,296
220,734
223,345
265,920
300,018
341,580
289,409
396,263
420,405
459,634
600,978
378,582
Working Capital
41,694
62,226
73,163
54,781
44,155
37,188
28,874
3
2
10,296
10,754
18,649
15,986
18,457
19,589
18,102
15,213
LT Debt
442,115
489,856
520,074
551,196
560,212
618,389
681,873
664,019
685,745
724,873
813,939
923,022
1,073,847
1,142,581
1,303,862
1,400,889
1,173,215
Total Equity
13.75
11.74
8.42
7.52
5.98
9.43
8.92
7.84
8.97
11.16
15.38
15.74
- -
20.09
18.24
18.93
21.02
Return on Invested Capital (%)
17.78
9.72
8.94
7.41
4.26
8.57
9.59
1.22
5.11
6.51
13.26
15.61
- -
15.15
19.94
17.48
15.64
Return on Capital (%)
15.86
10.66
9.82
8.03
4.51
9.19
10.24
1.33
5.28
6.74
13.73
16.22
17.09
14.48
19.68
17.22
20.75
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
ST Debt
6,393
- -
40,531
LT Borrowings
4,640
- -
357
LT Finance Leases
13,817
- -
14,856
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
183
183
183
Market Capitalization
1,588,079
1,872,916
1,688,114

Working Capital

FRC

•

in mil. unless spec.
Dec'23
Mar'24
Jun'24
Total Current Assets
534,913
- -
545,884
Cash, Cash Equivalents & STI
88,186
- -
57,854
Accounts Receivable, Net
204,968
- -
234,136
Inventories
177,767
- -
205,752
Total Current Liabilities
114,508
- -
167,302
Payables & Accruals
- -
- -
- -
ST Debt
6,393
- -
40,531
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.66%
11.54%
7.44%
Free Cash Flow
-298.03%
-602.33%
-2.62%
Net Income, GAAP
48.57%
19.23%
-2.89%
Sales/Revenue/Turnover
10.03%
10.74%
8.33%
Total Cash Common Dividend
45.86%
62.25%
17.7%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
203,432
216,261
- -
- -
857,545
2025
224,024
241,485
- -
- -
928,962
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
373
- -
- -
- -
1,307.23
2025
373
- -
- -
- -
1,270.58
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
- -
- -
432.09
2025
0.01
- -
- -
- -
509
2026
- -
- -
- -
- -
- -
Similar Companies
Impax Laboratories, Inc. (IPXL)
Ligand Pharmaceuticals Incorporated (LGNYZ)
Interpharm Holdings, Inc. (IPAH)
POZEN Inc. (POZN)
Kwality Pharmaceuticals Limited (KPL.BO)
Bristol-Myers Squibb Company (BMY.SW)
Business
Gedeon Richter Plc. (RGEDF) is a Hungarian multinational pharmaceutical company that develops, manufactures and markets specialty, biosimilar and generic medicines with a focus on central nervous system disorders, women's healthcare, cardiovascular treatments and biotechnology products; its core offerings include neuropsychiatric drugs such as Cariprazine, women's health solutions for contraceptives, endometriosis, fertility (including BEMFOLA recombinant FSH), menopause, vaginal infections and uterine fibroids, active pharmaceutical ingredients, biosimilars like denosumab and tocilizumab, multiple sclerosis therapies, and general medicines through its pharmaceuticals, wholesale/retail and other segments. Headquartered in Budapest, Hungary, and founded in 1901 by pharmacist Gedeon Richter, the company operates manufacturing facilities, representative offices and subsidiaries across more than 100 countries, primarily in Central and Eastern Europe, with a growing presence in the US and global markets; it maintains Central Europe's largest R&D hub and provides contract development and manufacturing organization services for APIs and biologics. Recent developments include a strategic investment and collaboration with Granata Bio in 2025 for US fertility market expansion, featuring equity acquisition, board representation, co-development of BEMFOLA and royalty agreements for human menopausal gonadotropin; positive CHMP opinion on denosumab biosimilars, filing of tocilizumab biosimilar in Europe, co-development and license agreement with Adalvo for semaglutide injection, launches of multiple sclerosis products in Europe, and strong revenue growth in 2025 driven by 13.7% increase in Cariprazine sales.

Company News

APIChatGPT

  • seekingalpha.com

    Gedeon Richter PLC (GEDSF) Q1 2026 Earnings Call Transcript